China NT Pharma Group Full Year 2023 Earnings: CN¥0.017 loss per share (vs CN¥0.035 loss in FY 2022)

China NT Pharma Group (HKG:1011) Full Year 2023 Results

Key Financial Results

• Net loss: CN¥33.5m (loss narrowed by 50% from FY 2022).
• CN¥0.017 loss per share (improved from CN¥0.035 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

China NT Pharma Group shares are down 33% from a week ago.

Risk Analysis

You still need to take note of risks, for example - China NT Pharma Group has 4 warning signs (and 3 which don't sit too well with us) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.